AssayGate

Executive Summary

AssayGate is a private diagnostics company based in San Diego, offering cost-effective protein biomarker assay and cytokine testing services on ELISA, MSD, and Simoa platforms. Founded in 2008, the company has established itself as a reliable partner for researchers and pharmaceutical companies needing accurate, reproducible assay results. Its service-oriented model, leveraging multiple high-sensitivity platforms, positions it well in the competitive biomarker testing market. However, limited public information on financials, funding, and pipeline makes a detailed assessment challenging. The company likely operates on a contract research basis, serving clients in drug development and academic research. Given the growing demand for biomarker validation and cytokine profiling, AssayGate's services are relevant, but its private status and sparse disclosure constrain conviction.

Upcoming Catalysts (preview)

• Q4 2026Expansion into new biomarker testing panels (e.g., neurology or immuno-oncology)50% success
• Q2 2027Partnership with a mid-sized biotech for clinical trial assay services30% success
• Q3 2026Adoption of next-generation Simoa HD-X platform for ultra-sensitive multiplex assays60% success